Core Viewpoint - The company plans to reappoint Lixin Certified Public Accountants (Special General Partnership) as its auditing firm for the fiscal year 2025, pending approval from the shareholders' meeting [1]. Group 1: Auditor Information - Lixin Certified Public Accountants was founded in 1927 by Dr. Pan Xulun and is a member of the international accounting network BDO [1]. - As of the end of 2024, Lixin has 296 partners, 2,498 registered accountants, and a total of 10,021 employees [2]. - Lixin has a professional risk fund of 171 million yuan and a cumulative insurance coverage limit of 1.05 billion yuan for professional liability [2]. Group 2: Legal and Regulatory History - Lixin has faced five administrative penalties and 43 supervisory measures in the past three years, with no criminal penalties [5]. - The firm has been involved in civil lawsuits related to securities false statements, with judgments requiring Lixin to cover a portion of compensation liabilities [4][5]. Group 3: Audit Project Information - The audit fee for the fiscal year 2024 is set at 700,000 yuan, with internal control audit fees at 50,000 yuan [6]. - The audit committee has reviewed Lixin's professional competence and independence, recommending its reappointment [7]. Group 4: Approval Process - The board of directors approved the reappointment of Lixin on August 26, 2025, and will submit the decision to the shareholders' meeting for final approval [7].

Core Viewpoint - The company is utilizing temporarily idle raised funds for cash management to enhance fund efficiency while ensuring that it does not affect the normal operation of its investment projects [1][8][12]. Fundraising Basic Information - The company raised a total of RMB 1,069,879,920.88 by issuing 70.6 million shares at a price of RMB 16.51 per share, with the funds received on August 25, 2022 [1][2]. Fund Management Agreements - The company and its subsidiary signed agreements with the sponsor and the bank to establish a special account for the management of raised funds, ensuring proper storage and management [2]. Investment Project Overview - The total investment amount for the projects funded by the raised capital is RMB 101,182.57 million [3]. Previous Cash Management - The company approved the use of up to RMB 75,000 million of temporarily idle funds for cash management, with a validity period of 12 months from the board's approval [3][4]. Current Cash Management Plan - The company plans to use up to RMB 65,000 million of temporarily idle funds for cash management, focusing on high-security and liquid investment products [7][8]. Impact on Daily Operations - The cash management will not affect the company's main business operations and aims to improve the efficiency of fund usage, benefiting the company and its shareholders [8][12]. Decision-Making Process - The board and supervisory board approved the cash management plan, ensuring compliance with relevant laws and regulations [11][12]. Sponsor's Opinion - The sponsor has no objections to the cash management plan, confirming that it complies with regulatory requirements and does not alter the purpose of the raised funds [12][13].

每经AI快讯，微电生理（SH 688351，收盘价：25.18元）8月26日晚间发布公告称，公司审议通过了 《关于聘任证券事务代表的议案》，同意聘任林艺珊女士为公司证券事务代表，协助董事会秘书开展日 常工作。 （记者 王晓波） 2024年1至12月份，微电生理的营业收入构成为：医疗器械占比98.48%，其他业务占比1.52%。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 截至发稿，微电生理市值为118亿元。 ...

核查意见 华泰联合证券有限责任公司关于 上海微创电生理医疗科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作 为上海微创电生理医疗科技股份有限公司（以下简称"微电生理"或"公司"） 首次公开发行股票并在科创板上市的保荐人及持续督导机构，根据《证券发行上 市保荐业务管理办法》《科创板上市公司持续监管办法（试行）》《上海证券交 易所科创板股票上市规则（2025 年 4 月修订）》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作（2025 年 5 月修订）》《上市公司募集 资金监管规则》等相关法律、法规和规范性文件的规定，对微电生理使用部分暂 时闲置募集资金（含超募资金）进行现金管理的事项进行了核查，具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2022]1587 号文《关于同意上海微创电 生理医疗科技股份有限公司首次公开发行股票注册的批复》，并经上海证券交易 所同意，公司于 2022 年 8 月 19 日向社会公众公开发行普通股（A 股）股票 7,060.00 万股，每股面值 1 元，每股发行 ...

证券日报网讯8月26日晚间，微电生理发布公告称，同意聘任林艺珊女士为公司证券事务代表。 ...

格隆汇8月26日丨微电生理(688351.SH)发布2025年半年度报告，报告期实现营业收入2.24亿元，同比增 长12.80%；归属上市公司股东的净利润3266.81万元，同比增长92.02%；扣除非经常性损益后的归属于 上市公司股东的净利润2080.63万元，同比增长2157.44%；基本每股收益0.0694元。 ...

证券代码：688351 证券简称：微电生理 公告编号：2025-015 上海微创电生理医疗科技股份有限公司 第三届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 监事会认为：公司 2025 年半年度报告及其摘要的编制符合法律、法规的规 定，报告内容真实、准确、完整地反映了公司 2025 年半年度的实际经营情况， 不存在虚假记载、误导性陈述或者重大遗漏。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《上 海微创电生理医疗科技股份有限公司 2025 年半年度报告》《上海微创电生理医疗 科技股份有限公司 2025 年半年度报告摘要》。 表决结果：赞成票 3 票；反对票 0 票；弃权票 0 票。 2、审议通过《关于<2025 年半年度募集资金存放与实际使用情况的专项报 告>的议案》 1 监事会认为：公司严格按照《上市公司募集资金监管规则》《上海证券交易 所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法规 ...

微电生理8月26日晚间披露2025年半年报，上半年实现营业收入2.24亿元，同比增长12.8%；归母净利润 3266.81万元，同比增长92.02%；基本每股收益0.0694元。经营数据变动，主要原因是报告期内销售规 模增长，以及降本增效带来的利润增长。 ...

` [Definition of Terms](index=4&type=section&id=Definition%20of%20Terms) This section defines common terms used in the report, including company names, related parties, key industry competitors, and critical medical technology terms, ensuring accuracy and consistency in reading the report - Company Abbreviation: Everpace Medical[10](index=10&type=chunk) - Reporting Period: First half of 2025[10](index=10&type=chunk) - Complete Solution for 3D Cardiac Electrophysiology Equipment and Consumables: A comprehensive solution covering all necessary equipment and consumables for 3D cardiac electrophysiology procedures, including 3D electrophysiology mapping systems, mapping catheters, 3D radiofrequency ablation catheters, radiofrequency ablation generators, irrigation pumps, and guiding sheaths[10](index=10&type=chunk) - PFA (Pulsed Field Ablation): A technique that applies short-duration, high-voltage pulsed electric fields to target tissue, disrupting cell lipid bilayers to form irreversible micropores, ultimately leading to cell apoptosis or necrosis, thereby ablating abnormal myocardial tissue and blocking abnormal electrical signal conduction[11](index=11&type=chunk) [Company Profile and Key Financial Indicators](index=5&type=section&id=Company%20Profile%20and%20Key%20Financial%20Indicators) This section provides an overview of the company's basic information and key financial performance for the first half of 2025 [I. Company Basic Information](index=5&type=section&id=I.%20Company%20Basic%20Information) This section introduces the company's basic information, including its Chinese name, abbreviation, legal representative, registered address, office address, website, and email address - Company Chinese Name: Shanghai MicroPort EP Medical Technology Co., Ltd[13](index=13&type=chunk) - Legal Representative: YIYONG SUN[13](index=13&type=chunk) - Company Website: www.everpace.com[13](index=13&type=chunk) [II. Contact Person and Contact Information](index=5&type=section&id=II.%20Contact%20Person%20and%20Contact%20Information) This section provides contact information for the company's Board Secretary and Securities Affairs Representative, including name, address, phone, fax, and email - Board Secretary: Zhu Yu[14](index=14&type=chunk) - Contact Number: 021-60969600-53608[15](index=15&type=chunk) - Email: investors@everpace.com[15](index=15&type=chunk) [III. Information Disclosure and Location Change Brief](index=6&type=section&id=III.%20Information%20Disclosure%20and%20Location%20Change%20Brief) This section discloses the company's selected newspapers for information disclosure, the website address for semi-annual reports, and the location where reports are kept - Company's Selected Newspapers for Information Disclosure: China Securities Journal, Shanghai Securities News, Securities Times, Securities Daily[16](index=16&type=chunk) - Website Address for Semi-Annual Reports: www.sse.com.cn[16](index=16&type=chunk) [IV. Company Stock/Depositary Receipt Summary](index=6&type=section&id=IV.%20Company%20Stock%2FDepositary%20Receipt%20Summary) This section introduces the listing exchange, stock abbreviation, and stock code for the company's A-shares - Stock Type: A-shares[17](index=17&type=chunk) - Stock Exchange and Board: Shanghai Stock Exchange STAR Market[17](index=17&type=chunk) - Stock Code: 688351[17](index=17&type=chunk) [VI. Company's Key Accounting Data and Financial Indicators](index=6&type=section&id=VI.%20Company%27s%20Key%20Accounting%20Data%20and%20Financial%20Indicators) This section outlines the company's key accounting data and financial indicators for the first half of 2025, showing significant growth in operating revenue, total profit, and net profit, especially a substantial increase in net profit after deducting non-recurring gains and losses 2025 First Half Key Accounting Data and Financial Indicators | Indicator | Current Period (Jan-Jun) (RMB) | Prior Year Period (RMB) | Period-over-Period Change (%) | | :--- | :--- | :--- | :--- | | Operating Revenue | 223,748,530.83 | 198,364,587.44 | 12.80 | | Total Profit | 32,816,628.64 | 17,032,732.92 | 92.67 | | Net Profit Attributable to Shareholders of Listed Company | 32,668,127.26 | 17,012,670.68 | 92.02 | | Net Profit Attributable to Shareholders of Listed Company After Deducting Non-Recurring Gains and Losses | 20,806,323.47 | 921,677.69 | 2,157.44 | | Net Cash Flow from Operating Activities | 64,366,377.38 | 37,921,452.48 | 69.74 | | Basic Earnings Per Share (RMB/share) | 0.0694 | 0.0362 | 91.71 | | Basic Earnings Per Share After Deducting Non-Recurring Gains and Losses (RMB/share) | 0.0442 | 0.0020 | 2,110.00 | | R&D Investment as % of Operating Revenue | 20.64 | 22.56 | Decrease of 1.92 percentage points | - Total profit, net profit attributable to shareholders of the listed company, net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses, basic earnings per share, diluted earnings per share, and net cash flow from operating activities all significantly increased compared to the same period last year, primarily due to sales scale growth and profit growth from cost reduction and efficiency improvement during the reporting period[21](index=21&type=chunk) [VIII. Non-Recurring Gains and Losses Items and Amounts](index=7&type=section&id=VIII.%20Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) This section details the company's non-recurring gains and losses items and their amounts for the first half of 2025, with an explanation for the one-time recognition of share-based payment expenses 2025 First Half Non-Recurring Gains and Losses Items and Amounts | Non-Recurring Gains and Losses Item | Amount (RMB) | | :--- | :--- | | Gains and losses from disposal of non-current assets, including the reversal of impairment provisions for assets | 726,244.50 | | Government subsidies recognized in current profit and loss, excluding those closely related to the company's normal business operations, compliant with national policies, enjoyed according to fixed standards, and having a continuous impact on the company's profit and loss | 5,757,847.08 | | Gains and losses from changes in fair value of financial assets and liabilities held by non-financial enterprises, and gains and losses from disposal of financial assets and liabilities, excluding effective hedging activities related to the company's normal business operations | 9,866,334.97 | | Other non-operating income and expenses apart from the above items | -2,154,072.97 | | Other profit and loss items that meet the definition of non-recurring gains and losses (one-time recognized share-based payment expenses) | -2,334,549.79 | | Total | 11,861,803.79 | - One-time recognized share-based payment expenses (RMB -2,334,549.79) are classified as non-recurring gains and losses because if shares are immediately granted or transferred without explicit vesting periods or other restrictions, share-based payment expenses should generally be recognized in the period of occurrence as an incidental item and included in non-recurring gains and losses[25](index=25&type=chunk) [Management Discussion and Analysis](index=8&type=section&id=Management%20Discussion%20and%20Analysis) This section provides a comprehensive discussion and analysis of the company's operations, financial performance, core competitiveness, and risk factors during the reporting period [I. Industry and Main Business Overview during the Reporting Period](index=8&type=section&id=I.%20Industry%20and%20Main%20Business%20Overview%20during%20the%20Reporting%20Period) This section elaborates on the company's industry positioning, main business, and market prospects in the field of electrophysiology interventional diagnosis and ablation therapy, highlighting its status as the first domestic manufacturer to provide a complete solution for 3D cardiac electrophysiology equipment and consumables, and noting that population aging will drive increased demand in the electrophysiology market - The company primarily engages in the research, development, production, and sales of innovative medical devices in the field of electrophysiology interventional diagnosis and ablation therapy[27](index=27&type=chunk) - The company is one of the few manufacturers in the global market with a complete product line for both electrophysiology equipment and consumables, and the first domestic manufacturer capable of providing a complete solution for 3D cardiac electrophysiology equipment and consumables[27](index=27&type=chunk) - As of the end of 2024, China's elderly population aged 65 and above reached 220 million, accounting for 15.6% of the total population, with population aging expected to further increase the number of atrial fibrillation patients, leading to a rapid increase in demand for the electrophysiology market[28](index=28&type=chunk) - In 2023, China had 11.132 million hospitalized patients with arrhythmias, with approximately 347,000 ablation procedures performed for various arrhythmias, including 338,000 interventional catheter ablations, and 147,000 ablation procedures for atrial tachycardia/atrial flutter/atrial fibrillation[29](index=29&type=chunk) [II. Discussion and Analysis of Operations](index=9&type=section&id=II.%20Discussion%20and%20Analysis%20of%20Operations) During the reporting period, the company focused on advantageous products, accelerated international expansion, and deepened budget control, achieving steady growth in operating revenue and net profit attributable to the parent company. Clinical recognition of core domestic products improved, especially with significant breakthroughs in atrial fibrillation treatment, while multi-technology routes synergistically advanced, showcasing innovative achievements on the international stage. The company continued

证券代码：688351 证券简称：微电生理 公告编号：2025-018 上海微创电生理医疗科技股份有限公司 关于2025 年度"提质增效重回报" 行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为落实国务院《关于加强监管防范风险推动资本市场高质量发展的若干意 见》《关于进一步提高上市公司质量的意见》相关要求，践行"以投资者为本" 的发展理念，进一步提高公司经营质量，增强投资者回报信心，提升投资者获得 感，上海微创电生理医疗科技股份有限公司（以下简称"公司"）制定了《2025 年度"提质增效重回报"行动方案》，并于 2025 年 8 月 26 日召开第三届董事会 第十六次会议审议通过了该方案。方案内容具体如下： 一、深耕电生理领域，提升核心竞争力 公司以研发和提供心脏电生理介入诊疗领域的完整解决方案为核心，持续推 动技术创新，是全球少数同时拥有电生理设备和耗材全产品线生产能力的厂商。 依托多年技术积累，公司攻克了三维磁电双定位技术、磁导航定位等关键技术， 成为国内首个实现三维电生理设备和耗材全面布局的企业。截 ...